A Randomized, Subject and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Mavoglurant (Primary)
- Indications Cocaine abuse
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 Jan 2018 Planned End Date changed from 19 Apr 2019 to 11 Mar 2019.
- 02 Jan 2018 Planned primary completion date changed from 19 Apr 2019 to 11 Mar 2019.
- 02 Jan 2018 Status changed from not yet recruiting to recruiting.